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ABSTRACT 
Laparoscopic surgery has proved to be a safe option in the surgical treatment of colon 
cancer, with better short-term results and similar oncologic outcomes when compared to 
conventional surgery. However, there has been some skepticism towards the use of 
laparoscopy to treat rectal cancer, particularly regarding long-term oncologic outcomes. 
Two central setbacks are the demanding surgical techniques and the lack of prospective 
randomized clinical trials. This review presents the current evidence regarding the 
oncologic outcomes achieved with laparoscopy versus laparotomy for the treatment of 
rectal cancer, including conversion, local recurrence, positivity of circumferential 
margins, lymph node harvest, and overall and disease-free survival rates.  
Conversion rate varied widely among studies, from 0 to 34%, with lower rates reported 
by more recent studies. Local recurrence, surgical margins positivity and lymph node 
harvest rates were similar in both surgical techniques. Some studies reported higher 
survival rates with laparoscopy, while others reported laparotomy advantage. However, 
these differences were not statistically significant and none of the studies reported a 
clear domain of one surgical technique over the other. 
Concerns about compromise of long-term oncologic outcomes are not supported by 
current literature. Expert hands and appropriate patient selection are certainly key 
factors - laparoscopic may not be suitable for all rectal cancers, but it could be safe and 
successful in selected patients when performed by experienced surgeons. 
Results of ongoing trials (COLOR II, ACOSOG-Z6051 and COREAN) are eagerly 
awaited to define the role of laparoscopic resection for the treatment of rectal cancer. 
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1. INTRODUCTION 
Colorectal cancer is one of the most frequent cancers worldwide, with 1,2 million new 
cases and 608700 deaths in 2008, and being surgery the cornerstone of its treatment, it 
is not complicated to understand that the surgical techniques may have an especially 
significant impact on the oncologic outcomes. 
Laparoscopic approach became attractive for its potential in reducing surgical trauma 
while maintaining oncologic outcomes. Studies evaluating the impact of the surgical 
approach have verified a decrease in blood loss during surgery, less post-operative 
surgical pain (reduced consumption of analgesic medication), earlier return of bowel 
function, and shorter length of hospital stay, offering safe and esthetically pleasing 
alternatives to conventional methods at the same time. Major surgery induces surgical 
stress with increased demands on patient’s reserves, and major inflammatory and 
immunological responses are triggered. Besides that, trauma causes endocrine and 
metabolic changes as well. Laparoscopy, by reducing surgical trauma, could attenuate 
those responses. This could begin to explain the reduced postoperative morbidity 
associated with this surgical approach. [1] For all these reasons, laparoscopic surgery 
has become the gold-standard for many procedures over the past decade. [2]  
Laparoscopy surgical techniques have been performed to treat colorectal cancer for 
more than two decades, as the first publications of laparoscopic application to the 
treatment of colon cancer date from 1991. [2] Port-site metastasis and incomplete 
oncologic clearance instantly became two main concerns and challenged the safety of 
laparoscopic procedures.  
Recent studies show a minimal port-site recurrence rate (<1%), comparable to open 
surgery, and defend that, in this setting, the way of handling the specimen extraction has 
more influence than the surgical approach. Therefore, laparoscopic surgery is now 
considered to be safe in this regard. [3,4] 
Large comparative studies and multiple prospective randomized control trials have 
demonstrated not only the short-term benefits of laparoscopy in the treatment of colon 
cancer, as they did before for other laparoscopic procedures, but also equivalent 
oncologic outcomes. [5-8]  
The Clinical Outcomes of Surgical Therapy (COST) and the COlorectal cancer 
Laparocopic or Open Resection I (COLOR I) trials were two large randomized clinical 
trials that randomly assigned 872 and 1248 patients, respectively, with colon cancer to 
either a laparoscopic or an open surgery group, and compared long-term outcomes 
between them, such as overall survival, disease-free survival and recurrence rates. There 
were no significant differences between the two surgical approaches in both studies. 
The absence of oncologic risk and the confirmation of the short-term benefits of 
laparoscopic surgery suggested that this approach could be feasible and become the gold 
standard for colon cancer treatment. [6,7] 
The Medical Research Council Conventional versus Laparoscopic-assisted Surgery in 
Colorectal Cancer (MRC CLASICC) trial was the only prospective randomized clinical 
trial to the date of its publication to include rectal cancer. Seven hundred and ninety four 
patients were randomly allocated to the laparoscopy or open surgery groups. Similarly 
to the previously mentioned trials, no differences were recorded between the two groups 
regarding short-term endpoints and mortality and recurrence rates. Regarding rectal 
cancer, laparoscopic anterior resection was associated with a higher but not statistically 
significant circumferential margin positivity rate. A conversion rate of 34% was 
reported, implying poorer outcomes for those patients. The 3-year, 5-year and 10-year 
follow-ups of MRC CLASICC trial confirmed the previous results relatively to overall 
survival and disease-free rates and showed no impact of the slightly higher positivity of 
circumferential resection on oncologic outcome. The long follow-up results suggest that 
laparoscopy in colon cancer not only is safe in oncologic terms, but should become the 
standard treatment. Regarding rectal cancer, results are not yet sufficient to recommend 
the routine use of laparoscopic resection as the treatment of rectal cancer. [8-11] 
Recent reviews summarizing randomized controlled trials information about 
laparoscopic results in colorectal cancer concluded that laparoscopic colectomy offers 
short-term postoperative benefits over conventional surgery, and that there is no 
justification not to recommend it to patients with colon cancer of any stage since the 
oncologic outcomes are not compromised. [12,13] 
On the other hand, as briefly mentioned before, laparoscopic rectal cancer was not 
welcomed with such enthusiasm. The lack of prospective randomized clinical trials 
addressing specifically the comparison between laparoscopy and open surgery for rectal 
cancer is an important drawback when examining long-term oncologic outcomes. 
This review presents the current evidence regarding the oncologic outcomes achieved 
with laparoscopy versus open surgery for the treatment of rectal cancer.  
 
2. LAPAROSCOPY IN RECTAL CANCER 
 
2.1. TOTAL MESORECTAL EXCISION: LAPAROSCOPIC TECHNIQUE 
Total mesorectal excision (TME) has been widely adopted for rectal cancer surgery over 
the past years, after having accomplished improved outcomes, particularly in regard to 
local recurrence, since it was introduced by Heald and Ryall during the 1980s. Some 
studies concluded that this procedure has reduced recurrence rates from between 30% 
and 40% to 5%. [14] 
The surgical technique provides excision of the intact mesorectum, and en bloc removal 
of the rectum and the tumor prevents micrometastases to remain in place. Posterior 
sharp dissection of the loose areolar tissue between the presacral fascia and the 
investing fascia of the mesorectum and anterior dissection performed through the 
Denonvillier’s fascia between the rectum and the prostate or posterior wall of the 
vagina, in men and women, respectively, are two important steps to accomplish 
complete mesorectum excision. Other TME principles include high ligation of the 
inferior mesenteric vessels (it facilitates mobilization of the splenic flexure and 
laparoscopic dissection in the anatomic planes, and could prevent potential intravascular 
dissemination of cancer cells during manipulation) and excision of the distal 
mesorectum of not less than 5 cm (in distal rectal cancers, a negative distal margin of 1 
to 2 cm may be acceptable); this should be confirmed to be tumor-free by frozen 
section. [15,16]  
Laparoscopic TME is not yet internationally standardized, but common surgical steps 
were adopted by several groups of surgeons. Leroy et al described the laparoscopic 
technique in 2002, and since then it has been used by many institutions. It proceeds as 
follows. Colorectal mobilization, vessel ligation, transaction and anastomosis are 
performed entirely laparoscopically. Five to six trocars measuring 5 to 12 mm are 
placed and excessive mobility is avoided by placing a suture to anchor the trocar to the 
abdominal wall. High ligation of the inferior mesenteric artery at its origin from the 
aorta with preservation of the left colic artery and lymphatic clearance of all lymph 
nodes at the base of the same artery are performed. The next step includes mobilization 
of the rectum as far down as possible on its posterior and right lateral surfaces before 
opening the anterior rectal space from right to left, extending from Douglas’s pouch. 
Complete rectal mobilization is accomplished after freeing the lateral attachments of the 
sigmoid colon, followed by the rectum, on its left lateral and posterior surfaces. The 
dissection is then continued down to the pelvic floor, alternating right lateral, left 
lateral, anterior, and posterior dissection. Sharp dissection between the parietal and 
visceral planes of the pelvic fascia is then performed to dissect the mesorectum. The 
pelvic autonomic nervous system, namely the hypogastric nerves and the autonomic 
branches of S2, S3 and S4 are identified and preserved, if possible. The rectum is 
completely excised within the visceral pelvic fascia and irrigation of the pelvis is carried 
out. Coloanal hand-sewn or double-stapling anastomosis can be performed if sphincter 
preservation is desired and feasible. The specimen is placed in an extraction bag and 
removed through a small suprapubic Pfannenstiel-type incision, with a plastic wound 
protector preventing contact. [2,15,16] 
Most of the published studies indicate safety and technical feasibility of the 
laparoscopic approach when performed by expert hands, with reduced perioperative 
morbidity and lower local recurrence rates, when compared to open TME. [2,15-17]  
Moreover, laparoscopy can provide a magnified view of the pelvis anatomy, allowing 
greater precision and better identification of important structures such as the nervous 
plexus, significantly aiding in their preservation and improving functional results. [16] 
Although technically more demanding, the possibility of faster standardization of the 
surgical procedure could also become an advantage of laparoscopic TME. [16] 
 
2.2. DIFFICULTIES IN LAPAROSCOPIC RESECTION OF RECTAL CANCER 
Laparoscopy techniques in rectal cancer are more challenging than the ones performed 
for colon cancer. There are specific questions related to rectal anatomy, such as difficult 
exposure in a narrow pelvis, proximity to nerve structures, difficult intestinal resection, 
and the need to control longitudinal and lateral resection margins. Especially in case of 
sphincter-saving TME with low anastomosis, technical issues regarding staplers can 
ensue, since it might not be feasible to perform a distal resection line in the low rectum 
exactly perpendicular to the longitudinal axis, and only with an acute angle to this axis.  
[2,16] Problems with anastomosis and difficulties in rectal transection, narrow pelvis, 
bulky tumors, adhesions and obesity are among the most common reported reasons for 
conversion and can represent relative contraindications to laparoscopy. Studies suggest 
that the open approach may be more suitable for these patients. [8,15,18-22] 
Challenges in this setting also include steep learning curves, longer operative time, 
concerns about the oncologic outcome, conversion risk and the lack of randomized 
controlled prospective trials declaring clear domain of laparoscopic over open surgery 
for rectal cancer treatment. [15,23] 
3. LAPAROSCOPIC VERSUS OPEN SURGERY: ONCOLOGIC 
OUTCOMES 
3.1. CONVERSION RATE AND ITS IMPACT ON SURGICAL OUTCOME 
Conversion rate records vary widely between studies. (table 1) [8,17-19,21,24-34] 
Several factors can influence the rate of conversion, such as the patient’s characteristics 
(age, Body Mass Index (BMI), American Society of Anesthesiology score), 
intraoperative difficulties and surgeon’s experience. As previously mentioned, 
conversion may be the result of problems with anastomosis and difficulties in rectal 
transection, narrow pelvis, bulky tumors, adhesions and obesity and, in those cases, an 
open approach may be more suitable. [8,15,18-21,26] 
The impact of conversion on surgical and oncologic outcomes is not completely 
understood yet and inconsistent results have been published. Some studies defended that 
conversion rates can result in poorer outcomes, while others found no significant 
differences in postoperative and oncologic outcomes between laparoscopic and 
converted patients. [8,15,18,19,21,29,30]  
It is critical to keep in mind the importance of completing surgery in an oncologically 
safe manner over completing it laparoscopically. The decision to convert must be made 
before there is any compromise of resection margins, in order to prevent condemning a 
patient to R1 resection and local recurrence. [35]  
Yamamoto et al, in a retrospective analysis of 1073 patients with rectal carcinoma 
undergoing laparoscopic surgery, reported a conversion rate of 7,3%. Patients requiring 
conversion had higher BMI (24,6 versus 22,7; p<0,001), higher rates of anterior 
resections, and higher morbidity rates (43,6% versus 21,1%). This was the first study 
with a large number of patients to suggest that conversion has negative effects on short-
term outcomes in rectal carcinoma. [19] 
Rottoli et al analyzed data from a prospective database of laparoscopic rectal resection 
performed in 173 patients with rectal cancer, and found a conversion rate of 15%. 
Converted (CR) patients had a mean BMI of 27,3 while not converted (NCR) had a 
BMI of 24,9 (p<0,001). The number of patients with stage IV disease was significantly 
higher among CR patients (26,9% versus 4,8% of NCR patients; p<0,001). No 
statistically significant differences were reported between groups regarding 5-year 
overall and disease-free survival. The authors showed a trend toward CR patients 
having higher overall recurrence rates. In summary, in this study, BMI and stage IV 
disease were predictor factors associated with conversion, and although conversion did 
not affect post-operative immediate results, it could have an important impact on long-
term outcomes. [18] 
Thorpe et al stated that male sex could be an important factor for conversion and 
Laurent et al reported a 3-fold higher conversion rate for men with stapled anastomosis. 
[15]  
MRC CLASICC reported, as previously mentioned, a 34% conversion rate, which was 
reduced in every year of recruitment, reflecting the impact that the learning curve can 
have on the conversion rate. Patients undergoing conversion had higher in-hospital 
mortality and complication rates. Conversion was more common among advanced 
cancers and patients with higher BMI. [8] 
In a prospective series of 389 patients with rectal cancer, Strohlein et al reported an 
increase in metachronous metastasis and local recurrence in the converted group, 
compared with either completed laparoscopic resection or open surgery. [36]  
Other studies reported lower conversion rates. Rottoli et al and Laurent et al registered 
15% conversion rates, Law et al 12,5%, Lujan et al 7,9%, Ng SS et al 7,5%, Yamamoto 
et al 7,3% and Li et al 5,3%. [18,19,24,27,28,31,32] Of these, Law et al registered a not 
statistically different but suggestive higher rate of local recurrence for those requiring 
conversion (16,9% versus 6,9%; p=0,108) [28]. Even lower conversion rates have been 
reported by Leroy et al (3%), Tsang et al (1,9%) and Bärlehner et al (1%). [17,25,34] 
This could be due to technological advances, surgeon experience, and more careful 
patient selection, particularly regarding obese patients, anterior resections, and advanced 
tumors.  
Hotta et al selected studies with a large number of patients undergoing laparoscopic 
surgery published between 2000 and 2009 and noticed a range of 1% to 21,9% 
regarding conversion rate. [21] Two meta-analyses, including only randomized clinical 
trials, also found a significant range regarding conversion rate, from 0% to 34%. [29,30]  
The COLOR II randomized clinical trial reported recently its short-term outcomes and 
the conversion rate reported was 17%. The reasons for conversion were similar to the 
ones mentioned before. [26] 
 
TABLE 1 – CONVERSION RATES 
STUDY TYPE OF STUDY NUMBER OF 
PATIENTS 
CONVERSION 
RATE, % 
MRC CLASICC 
8
 RCT L=242 34,0 
Ng SS et al 
29
 RCT L=76 30,0 
Morino et al 
29
 Nonrandomized 
comparative study 
L=98 18,4 
COLOR II 
26
 RCT L=699 17,0 
Laurent et al 
27
 Retrospective 
comparative study 
L=238 15,1 
Rottoli et al 
18
 Case series L=173 15,0 
Law et al 
28
 Nonrandomized 
comparative study 
L=111 12,5 
Ng SS et al 
33
 RCT L=51 9,8 
Lujan et al 
31
 RCT L=101 7,9 
Ng SS et al 
32
 RCT L=40 7,5 
Yamamoto et al 
19
 Case series L=1073 7,3 
Braga et al 
29
 RCT L=83 7,2 
Ng KH 
29
 Case series L=579 5,4 
Li et al 
24
 Nonrandomized 
comparative study 
L=113 5,3 
Leroy et al 
17
 Case series L=102 3,0 
Tsang et al 
34
 Case series L=105 1,9 
Bärlehner et al 
25
 Case series L=194 1,0 
RCT=randomized clinical trial; L=laparoscopy 
 
3.2. SURGICAL MARGINS, LYMPHADENECTOMY AND LOCAL 
RECURRENCE RATES 
Since the introduction of laparoscopy in the treatment for colorectal cancer that one of 
the main concerns was whether it provides rectal excision equivalent to the open 
procedure, with adequate lymphadenectomy and radial and circumferential clearance in 
order to avoid recurrence of cancer. 
As previously mentioned, TME excision has reduced the local recurrence rate in a 
remarkable way and, at present, it is considered equivalent to open TME. 
Negative surgical margins are crucial to avoid local recurrence. Circumferential margin 
positivity is considered an independent factor in local recurrence. [15,16] Radial 
margins <2cm are related to a 16% local recurrence rate, contrasting with a 6% rate if 
the radial margin is >2cm. [16,37] The distal resection margin is still controversial, but 
most surgeons consider a 2 cm distal margin acceptable. [15] 
The number of lymph nodes (LN) harvested during surgery varies widely. For a correct 
pathological staging, removal of 12 LN is advised, but most series report lower number 
of harvested LN. This could be due to the chemoradiotherapy regimens that are applied. 
However, high ligation of the inferior mesenteric vessels, which is now performed in 
laparoscopic TME, can help improve node harvest, allowing more accurate tumor 
staging. [15,16] 
Several meta-analyses and reviews report no difference between the two surgical 
approaches concerning the mean number of LN removed. [2,29,30,36,38] The meta-
analysis published by Anderson et al, which had 17 publications reporting the number 
of LN harvested, stated, however, open surgery advantage (12 LN versus 10 LN). [37] 
Lujan et al and Ng SS et al, on the other hand, showed laparoscopic advantage. [31,32]  
The MRC CLASICC trial reported similar LN harvest and positivity surgical margins 
rates in laparoscopic and open surgery groups, except in laparoscopic anterior rectal 
resection, where slightly higher but not statistically significant positive circumferential 
margin rates were verified. [8] However, the 3-year analysis of the same clinical trial 
showed no impact of that finding on oncologic outcome, including local recurrence 
rates. [9] These were comparable between the two surgical approaches (7,8% in 
laparoscopic resection and 7% in open surgery). [8] Surgeons in their learning curve, 
not standardized preoperative chemoradiotherapy and advanced tumors could have 
contributed to the initial alarming results. [8] Similarly, Laurent et al found non-
significant higher circumferential margin positivity rates associated with laparoscopic 
approach, in a retrospective comparative study that focused on intersphincteric resection 
for low rectal cancer. Possible explanations for this fact are the more distal nature of 
tumors and also the more frequent involvement of the internal sphincter in the 
laparoscopic group. [39] On the other hand, Lujan et al, in a recent large prospective 
multicentre analysis of 4970 patients, reported significantly higher circumferential and 
distal margin involvement in the open group, although it did not affect local recurrence 
and survival after a follow-up of 22 months. [40] 
Kirzin et al showed similar invasion of distal and circumferential resection margins for 
both procedures, which is comparable to previously reported results of Huang et al and 
Ohtani et al, and Anderson et al and Gao et al respectively. [2,29,37,38] Anderson et al 
published circumferential margin positivity rates of 5% and 8% and distal margin 
positivity rates of 1% and 0,6% for laparoscopy and open approach, respectively. In 
what concerns margin distance, there were not significant differences registered as well. 
These values are comparable to other meta-analyses. [37] 
Local recurrence rates have not ranged wildly between studies and were similar between 
laparoscopic and open surgery. [13,17,24,26-28,31,37]  
As previously mentioned, MRC CLASSIC reported rates of 7,8% and 7% for 
laparoscopic and open surgery, respectively. [8] Laurent et al revealed no difference 
between open and laparoscopic rectal excision concerning recurrence rates at five years 
(5,5% versus 3,9%; p=0,371) in a retrospective comparative study in which 233 patients 
with rectal cancer were treated by open surgery and 238 by laparoscopy. [27] Law et al, 
who compared the outcome of open and laparoscopic resection for stage II and III rectal 
cancer, found no differences in local recurrence rates. [28] 
Lujan et al, in a single centre randomized controlled trial in which 204 patients with 
middle and low rectal cancers were randomized to either open or laparoscopic resection, 
found rates of 5,3% and 4,8% of 5-year local recurrence, respectively. [31] Li et al also 
focused on middle and low rectal cancers, and reported no differences between 
laparoscopy and laparotomy regarding surgical margins, LN harvest, and local 
recurrence rates at 5 years (9,1% versus 6,4%, respectively). [24]  
Leroy et al reported a rate of local recurrence of 6%. All but one of the pelvic 
recurrences occurred in node-positive patients and all but one in patients who had 
received preoperative radiotherapy. This reflects the influence that other factors can 
have in local recurrence rates. Previously reported risk factors include N2 disease, 
perineural invasion and positive lateral margins. [17] 
 A multi-institutional series from Japan regarding 1057 patients that underwent 
laparoscopic resection of rectal cancer reported a slightly lower local recurrence rate of 
1%. [20] 
Anderson et al published overall local recurrence rates of 7% for laparoscopic and 8% 
for open resections in their meta-analysis of 24 studies. [37] The Cochrane systematic 
review of laparoscopic versus open TME for rectal cancer, published in 2006, reported 
similar local recurrence rates (7,2% versus 7,7%). [13]  
Recently published COLOR II trial results also showed no difference between 
laparoscopic and open surgery regarding proximal margins and positive circumferential 
resection margins after surgery for cancer located in the upper portion of the rectum. 
For low rectal cancer resection, laparoscopy allowed a lower rate of positive margins. 
[26] 
 
3.3. OVERALL AND DISEASE-FREE SURVIVAL 
In the MRC CLASICC trial, the overall survival was not influenced by the stage disease 
and rates were similar between the two surgical approaches, but conversion to 
laparotomy had a negative impact on the outcome. Five-year overall survival rates for 
conversion, laparotomy and laparoscopy were 49,6%, 58,5% and 62,4%, respectively 
(p=0,005). [10] Long-term results confirmed worse overall survival for converted 
patients (59,2 versus 78,4 and 94,8 months, respectively, p=0,001). [11] In contrast, in 
the study of Laurent et al, survival was not influenced by conversion. Cancer-free 
survival at 5 years was 82% and 79% after laparoscopy and laparotomy, respectively 
(p=0,52) and no difference according to tumor stage was noted. By contrast, 5-year 
overall survival was higher in the laparoscopic group (83% versus 79%) and this 
difference, although not statistically significant, was more pronounced in stage III 
cancers (78% versus 70% P=0,279). [27]  
Law et al also registered improved survival in the laparoscopic group. Five-year 
survival rates were 71,1% and 59,3% in the laparoscopic and open groups, respectively 
(P=0,029). [28] The same authors carried out another study that aimed to compare the 
overall and disease specific survivals of laparoscopy and laparotomy, to confirm 
previous findings in a cohort of larger number of patients with longer follow-up. 
Laparoscopy was one more time associated to better survival rates, particularly in 
cancer stages II and III. [41] It was suggested in this study that the improved survival 
associated with laparoscopy could be due to a better immunologic response. In fact, 
lower levels of tumor necrosis factor alpha, interleukin 1-6, vascular endothelial growth 
factor and C-reactive protein, which are responsible for the postoperative inflammatory 
response, have been associated with laparoscopy for some time. [1,41] 
Morino et al also noted a significantly longer cumulative survival for patients with more 
advanced cancers (stage III or IV) treated with laparoscopic surgery but it was the only 
individual author to do so in a meta-analysis by Anderson et al, who published a mean 
overall survival based on 13 studies of 72% for laparoscopic resections and 65% for 
open surgery at a mean follow-up period of 4,4 years (p=0,5). [37] 
Besides MRC CLASICC trial, other trials showed no difference between the two 
surgical approaches. Among them are the trial by Lujan et al (72,1% versus 75,3% for 
laparoscopy and laparotomy, respectively); the multicenter retrospective Japanese study 
involving 1057 patients; a comparative prospective study by Li S et al (77,9% versus 
78,9% at 5-years for laparoscopy and laparotomy, respectively) and a Chinese 
randomized clinical trial that analyzed 1-year, 2-year and 3-year survival rates. 
[21,24,31,42] Ng SS et al, in a small randomized trial involving 80 patients, published 5 
and 8-year overall survival rates of 85,9% and 82%, and 91,3% and 72,7% in 
laparoscopic and open surgery, respectively. These rates were similar between surgical 
approaches as well, but were slightly better than the ones reported by other trials. 
However, this finding could be due to the exclusion of abdominoperineal resections 
from the study. [32] 
A meta-analysis including six randomized controlled trials and 1033 patients also 
reported similar rates (p=0,11) in overall and disease-free survival. [38] 
Few studies have reported 5-year survival data. Most follow-ups are shorter than that, 
and longer-term outcomes are awaited. Some trials show better survival rates in the 
laparoscopic group, others in the open surgery group, reflecting inconsistency between 
studies. However, these differences are not statistically significant and none of the 
studies previously mentioned reported a clear domain of one surgical technique over the 
other. 
3.4. ONGOING TRIALS 
 
3.4.1. COLOR II 
COLOR II is the largest randomized trial to compare laparoscopic and open surgery for 
rectal cancer. This study was carried out between January 20, 2004 and May 4, 2010. Of 
the 1044 patients from 30 hospitals and centers in 8 countries available for analysis, 699 
were randomly assigned to laparoscopic surgery and 345 to open surgery (ratio 2:1). 
Patients with distant metastasis, T3 cancers within 2mm from the endopelvic fascia and 
T4 cancers were excluded. The primary endpoint in this trial was local recurrence at 3 
years, and secondary endpoints the short-term results, including operative findings, 
complications, mortality and pathological examination (completeness of the resection, 
surgical margins and number of harvested lymph nodes). 
The information concerning short-term outcomes was published recently. The authors 
concluded that the laparoscopic approach can achieve similar rates of intra-operative 
complications, morbidity and mortality. No difference was recorded between groups 
regarding proximal and circumferential resection margins positivity after surgery for 
cancer located in the upper portion of the rectum. For low rectal cancer resection, 
laparoscopy allowed a lower rate of positive margins. Long-term results on local 
recurrence and survival rates are awaited. [26] 
3.4.2. ACOSOG-Z6051  
This American study began in August 2008 and is a phase 3, prospective randomized 
clinical trial involving 650 patients. It compares laparoscopic-assisted resection with 
open surgery for rectal cancer, and its primary endpoint is to show that laparoscopy is 
not inferior to open resection in patients with stage IIA, IIIA or IIIB rectal cancer, 
regarding circumferential and distal margins and completeness of TME. Secondary 
endpoints include local recurrence and disease-free survival rates, and functional 
outcomes. [15] 
3.4.3. COREAN  
This trial was carried on from April 4, 2006 to August 26, 2009 and it was designed to 
assess the safety of laparoscopy compared with conventional surgery for mid and low 
rectal cancer after chemoradiotherapy. Patients with cT3N0-2 mid or low rectal cancer 
without distant metastasis were included in the study and randomized to receive open 
(n=170) or laparoscopic surgery (n=170). All patients received a fluoropyrimidine-
based chemoradiotherapy regimen preoperatively. The primary endpoint is 3-year 
disease-free survival. Secondary endpoints include involvement of the circumferential 
resection margin, number of harvested LN, and macroscopic quality of the TME 
specimen. 
LN harvest, proximal distal and radial resection margins, as well as circumferential 
resection margin positivity and macroscopic quality of TME specimen were similar 
between groups. Conversion rate was 1,2%. This trial was the first randomized trial 
focusing on the impact of preoperative chemoradiotherapy regimens, and it shows 
feasibility and safety of the laparoscopic procedure in expert hands after 
chemoradiotherapy, without jeopardizing short-term oncologic outcomes. Patients 
continue to be followed-up to assess 3-year disease-free survival. [43]  
4. DISCUSSION 
Laparoscopic surgery has proved to be a safe and feasible option in the surgical 
treatment of colon cancer, with better short-term results and similar oncologic outcomes 
when compared to conventional surgery. However, there has been some skepticism 
towards the use of the laparoscopic approach to treat rectal cancer, particularly 
regarding long-term oncologic outcomes. If these are not proven to be equivalent or 
better than the ones open surgery has to offer, the short-term advantages will not matter. 
A central setback in the acceptance of laparoscopy as a first-line treatment for rectal 
cancer is the lack of prospective randomized clinical trials with a large number of 
patients addressing specifically the comparison between laparoscopy and laparotomy 
and clearly stating the advantage of laparoscopy over open surgery in terms of 
oncologic outcomes. The bulk of available data comes from relatively small randomized 
control studies and larger non-randomized case series, since most of the published 
multicenter trials regarding colorectal cancer did not recruit patients with rectal cancer 
because the procedure is technically demanding. [13,32]   
The heterogeneity of protocols is an important aspect to consider when drawing 
conclusions. Follow-up periods varied widely. Exclusion criteria can lead to selection 
bias. Factors such as the lack of standardization of the surgical technique, type of 
procedure, localization and stage of the tumor, presence or absence of neoadjuvant and 
adjuvant radiochemotherapy, patient’s characteristics and surgeon’s experience can 
influence outcomes regardless of the surgical approach, and have to enter the equation 
as results are interpreted. [13]  
Oncologic safety can be measured by conversion rate, surgical margins positivity, 
number of LN harvested, local recurrence and survival rates, and that was the reason 
why those parameters were analyzed in this review. 
Conversion rates ranged widely, from 0% to values as high as 34%, with more recent 
studies reporting lower rates. This could be due to heterogeneity of clinical trials, 
different phases of the learning curve, and better patient selection. The most reported 
reasons for conversion were bulky tumors and obesity. Conversion seems to have a 
negative impact on surgical outcomes, but some inconsistent results have been 
published and this issue is not yet fully understood. Careful preoperative assessment of 
risk factors for conversion can help prevent it. [8,15,18-22] 
MRC CLASICC initially reported alarming results on circumferential surgical margins. 
However, 3-year outcomes did not show any impact on local recurrence. [8] Although 
other studies also reported lower rates of margin clearance associated with laparoscopy, 
these were not statistically significant. Moreover, most meta-analyses showed no 
difference between surgical approaches. The same happened with LN count and local 
recurrence rates, which were similar in laparoscopic and open surgery.  
Most follow-ups are relatively shorter and long-term survival has been published in 
very few studies, not allowing definitive conclusions. The survival rates reported have 
been similar and none of the studies found a clear domain of one surgical technique 
over the other in this regard. 
The surgeons’ experience is without doubt a factor with great importance in rectal 
cancer surgery, since it is technically demanding. Rectal cancer surgery requires more 
training time than colon cancer surgery, and laparoscopy more than laparotomy. This is 
why, for many surgeons, open surgery is still the chosen approach for treating rectal 
cancer. In the MRC CLASICC trial, the learning curve was estimated at 20 cases. [8] 
Multidimensional analysis of the learning curve for laparoscopic surgery were 
performed by various authors, and surgeons’ experience was related to less operating 
time, decision to perform protective diverting stoma and surgical site infection rate. [44-
46] The reduction of conversion rate and postoperative complications seemed to require 
higher number of cases, reflecting the need of mastery of the surgical technique by 
surgeons. [46] Park et al also analyzed the impact of surgeons’ experience and 
concluded that the learning curve for oncologic safety was longer. [47] The number of 
cases required to plateau in terms of speed, morbidity rate, conversion rate and 
oncologic adequacy remains debatable and varies extensively between studies. [35,44-
46] 
Recently, some studies have focused on the impact of the combination of fast-track 
programmes and laparoscopic technique. As they had a dramatic effect on perioperative 
outcomes in colorectal surgery, rectal cancer patients could be expected to benefit from 
them in the same manner. By reducing stress and pain with aggressive postoperative 
mobilization and early oral feeding, the body stress response and organ dysfunction are 
reduced to a minimum, thus improving postoperative morbidity and mortality rates. 
However, the lack of randomized clinical trials addressing these programmes directly 
does not allow consistent and definitive conclusions. For now, fast-track protocols seem 
promising. Nevertheless, one must not forget that surgeon’s experience is a crucial 
factor capable of improving outcome in rectal cancer surgery. Probably the combination 
of advanced surgical techniques and better perioperative care is the way to improve 
patients’ outcome. [23,48,49] 
Despite all the setbacks previously mentioned, randomized clinical trials suggest that 
laparoscopy is a safe, feasible option for the treatment of rectal cancer, offering 
improved short-term results compared to open surgery, without adversely affecting 
oncologic outcomes.  
Expert hands combined with appropriate patient selection may be the key to withdraw 
the best possible outcome from laparoscopic surgery. Some believe that the main 
question is not open versus laparoscopic surgery, but rather how to decide on the most 
suitable surgical technique for each patient, taking into consideration all the variables 
that can interfere with oncologic outcome. [50] Laparoscopic may not be suitable for all 
rectal cancers, but it could be safe and successful in selected patients when performed 
by experienced surgeons. [35]  
Recently, a report from the prospective COST trial concluded that age and tumor stage 
are the variables with most impact on survival, and surgical quality surrogates (surgical 
technique, LN count and surgical margins) were not prognostic. Although patients in 
this study had colon cancer, its conclusions are intriguing, and make one question about 
their reproducibility in the context of rectal cancer. Besides, it emphasizes the 
importance of patient selection for laparoscopy which, as previously seen, has a crucial 
role in rectal cancer surgery. [51]    
Concerns about compromise of LN harvest, conversion rate, circumferential margins 
and overall survival are not supported by current literature. However, there is a paucity 
of data concerning long-term oncologic outcomes. Results of COLOR II, ACOSOG-
Z6051 and COREAN trials are eagerly awaited to define the role of laparoscopic 
resection for the treatment of rectal cancer.   
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